FDA‐approved drug screen with in vivo validation thus provides a rationale for clinical evaluation of MYC inhibition, such as bortezomib in MYC‐driven neuroblastoma [45], and further experimental and clinical studies are warranted to validate efficacy of any MYC inhibition within ER+ or ER‐ breast cancer with MYC amplifications. This evidence concerns the gene ESR1 and neuroblastoma.